Medicare experimental denied: how to appeal

Quick answer

If Medicare (Original + Advantage) denied your experimental or investigational, you can appeal, and the plan must give you its file and the criteria it used. Filing windows by plan type: 120 days from the notice (Original Medicare); 65 days from the notice (Medicare Advantage); 65 days from the notice (Part D). The date printed on your denial notice controls; it can only be later than these floors, never earlier.

Why Medicare (Original + Advantage) denies experimental or investigational

Medicare is a federal program with two delivery modes, Original (fee-for-service Part A/B + Part D drug plans) and Advantage (private MA-C plans). Each has its own appeal ladder, and rights are stronger than most beneficiaries realize.

For experimental or investigational specifically: Carriers commonly deny coverage by labeling a treatment 'experimental' or 'investigational', a designation that bypasses the usual medical-necessity analysis. These denials are appealable, and many reverse when peer-reviewed evidence, compendia listings, or clinical-trial data are presented.

The law that controls this appeal

FDA approval for the indication, recognized compendia (NCCN, AHFS-DI, DrugDex), and CMS National Coverage Determinations defeat an 'experimental or investigational' label.

Note for Medicare (Original + Advantage): where the standard above cites ERISA or the ACA appeal rules, those describe employer and Marketplace plans. The windows and levels that apply to Medicare (Original + Advantage) are in the table below.

At a glance

Medicare (Original + Advantage) appeals: the rule, the deadline and the next level, by plan type

Original Medicare, Medicare Advantage and Part D each have their own federal ladder. The notice you received says which one you are in.

Plan type	Rule that governs	File your appeal within	The plan must answer	If the plan says no again
Original Medicare (Parts A and B) Fee-for-service Medicare. The Medicare Summary Notice lists the denial.	42 CFR Part 405, Subpart I.	Redetermination: 120 days from receipt of the initial determination (42 CFR 405.942). Reconsideration by a Qualified Independent Contractor: 180 days from the redetermination (§ 405.962). ALJ hearing: 60 days (§ 405.1002).	The Medicare Administrative Contractor decides a redetermination within 60 days (§ 405.950); the QIC decides within 60 days (§ 405.970).	QIC reconsideration, ALJ hearing (amount-in-controversy threshold), Medicare Appeals Council, federal district court. Fast-track appeals of service terminations go to the Quality Improvement Organization (42 CFR 405.1200 to 405.1206).
Medicare Advantage (Part C) A private plan that replaces Original Medicare. The card says Medicare Advantage, HMO, PPO or PFFS.	42 CFR Part 422, Subpart M (§§ 422.560 to 422.634). Coverage decisions must follow Original Medicare rules (42 CFR 422.101).	65 calendar days from the date on the denial notice to request the plan's reconsideration (42 CFR 422.582, as amended effective 1 January 2025).	Expedited: 72 hours. Standard pre-service: 30 days (7 days for Part B drugs). Payment: 60 days (42 CFR 422.590).	If the plan does not fully reverse itself it must send the case to the Independent Review Entity on its own (42 CFR 422.592); then an ALJ hearing when the amount in controversy meets the annual threshold, the Medicare Appeals Council and federal court. State external review does not apply.
Medicare Part D (drug plan or MA-PD) A stand-alone drug plan or the drug benefit inside a Medicare Advantage plan.	42 CFR Part 423, Subpart M; exceptions under 42 CFR 423.578.	65 calendar days from the date on the notice to request a redetermination (42 CFR 423.582, as amended effective 1 January 2025). Formulary, tiering and step-therapy exceptions need the prescriber's supporting statement (§ 423.578).	Redetermination: 7 calendar days standard, 72 hours expedited (42 CFR 423.590). Coverage determinations: 72 hours standard, 24 hours expedited, once the prescriber's statement is received (§§ 423.568, 423.572).	Independent Review Entity reconsideration on your request within 65 days of the redetermination notice (§ 423.600); then ALJ, Council and court.

Original Medicare (Parts A and B)

What you can demand. Follow the appeal instructions on the Medicare Summary Notice or use form CMS-20027. Your provider can appeal for you; any other representative needs form CMS-1696.

How to open the appeal. Cite 42 CFR 405.942 and the coverage rule that applies (the national or local coverage determination), and attach the treating clinician's statement addressed to each coverage criterion.

Medicare Advantage (Part C)

What you can demand. The plan may not apply internal criteria that are more restrictive than Medicare's national and local coverage determinations, and must decide medical necessity on your individual circumstances (42 CFR 422.101(b), (c)). You can ask for the case file and the criteria used.

How to open the appeal. Cite 42 CFR 422.582 and 422.101(c): the plan must decide on your individual circumstances under Medicare coverage rules, and must forward an unfavorable reconsideration to the IRE itself.

Medicare Part D (drug plan or MA-PD)

What you can demand. The exception turns on the prescriber's statement that the formulary alternative would be less effective or would harm you (42 CFR 423.578(b)(5)).

How to open the appeal. Cite 42 CFR 423.578 and 423.582 and attach the prescriber's supporting statement written to the exception standard.

Primary sources for this table

Windows are federal floors or the rule as written; the denial notice controls. Reviewed 13 September 2026. General information, not legal advice; Apellica is not a law firm.

What Medicare (Original + Advantage) denies for experimental or investigational

The experimental or investigational services most often denied:

Off-label oncology regimens
Newer CAR-T and cellular therapies
Proton beam therapy
Genetic and biomarker testing (next-generation sequencing)
Surgical techniques deemed novel
Compassionate-use and expanded-access drugs

Why experimental or investigational claims get denied

A typical Medicare (Original + Advantage) experimental or investigational denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

Treatment is not specifically FDA-approved for the indication
Plan policy bulletin lists the service as investigational
No randomized controlled trial cited in plan's policy
Service is not in a recognized compendium for the diagnosis

The Medicare (Original + Advantage) appeal process

Appeal levels: 5 federal levels. Each has its own deadline; the ALJ and court levels require the amount in controversy to meet the annual threshold CMS publishes.

Carrier timing: 120 days from the notice for level 1 in Original Medicare (redetermination) or 65 days for Medicare Advantage reconsideration (42 CFR 422.582). Later levels: 180 days for the QIC reconsideration in Original Medicare, then 60 days each.

Experimental timing for Medicare (Original + Advantage): the filing windows and decision clocks in the table above apply; the date on the notice controls.

What we know about Medicare (Original + Advantage): Medicare cases require a CMS-1696 Appointment of Representative form for us to act on your behalf. We provide this at intake.

Common Medicare (Original + Advantage) denial patterns for experimental or investigational

Original Medicare: 5-level appeal. Redetermination by MAC → reconsideration by QIC → ALJ hearing → Medicare Appeals Council → federal district court. The QIC and ALJ levels reverse a substantial share of denials when properly briefed.
Medicare Advantage: identical 5-level ladder. MA plans must follow the same federal appeal structure as Original Medicare. Plan-level reconsideration → Independent Review Entity (Maximus) → ALJ → Council → federal court.
Part D drug coverage denials. Part D appeals follow a separate but parallel ladder. Tiering exceptions and formulary exceptions are filed before a coverage determination challenge.

How to win your Medicare (Original + Advantage) experimental or investigational appeal

Strategy for experimental or investigational: Identify the plan's exact 'experimental/investigational' policy bulletin and rebut it point-by-point. Cite NCCN, ASCO, AHFS-DI, DrugDex, or other recognized compendia for the indication. Attach peer-reviewed literature and any clinical-trial enrollment data. Many state external review programs apply a heightened standard for E/I denials, once the case reaches external review, the IRO physician panel often overturns.

Filed against Medicare (Original + Advantage), that strategy rides on this procedural spine:

Procedural-rights anchor. Cite 42 CFR 405.942 and the coverage rule that applies (the national or local coverage determination), and attach the treating clinician's statement addressed to each coverage criterion. If your Medicare (Original + Advantage) coverage is a different plan type (Medicare Advantage, Medicare Part D), use that row of the table above instead; the rule and the deadline change with the plan, not the carrier.
Criteria-disclosure demand. Medicare (Original + Advantage) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
Controlling-standard citation. FDA approval for the indication, recognized compendia (NCCN, AHFS-DI, DrugDex), and CMS National Coverage Determinations defeat an 'experimental or investigational' label.
Treating-provider attestation. A letter from the treating physician addressing each criterion in Medicare (Original + Advantage)'s own policy language. This is the single strongest evidentiary element.
Requested action. A specific demand to reverse the experimental or investigational denial and approve the service, not a general "please reconsider."

Documents you'll need for your Medicare (Original + Advantage) experimental or investigational appeal

Denial letter (with plan's E/I policy bulletin)
Treating physician's letter of medical necessity
Peer-reviewed literature supporting the therapy
Compendium entry (NCCN, ASCO, AHFS-DI, DrugDex)
Pathology / diagnostic report

What a experimental or investigational appeal can recover

Typical recovery for experimental or investigational cases runs $5,000 - $500,000+ depending on therapy. The exact figure depends on the specific service and your plan's contracted rates.

Medicare (Original + Advantage) experimental or investigational appeals: frequently asked questions

What beats an 'experimental' label?

FDA approval for the specific indication, a recognized compendium entry (NCCN, AHFS-DI, DrugDex), a CMS national coverage determination, and peer-reviewed literature. Many state external-review programs apply a heightened standard for these denials.

Why does Medicare (Original + Advantage) call a standard treatment experimental?

Usually because the therapy is not specifically FDA-approved for that indication, the plan's bulletin lists it as investigational, or no randomized trial is cited in the policy. A compendium entry for your diagnosis directly contradicts that classification.

What Apellica does for Medicare (Original + Advantage) experimental or investigational appeals

We file appeals against Medicare (Original + Advantage) specifically configured to its internal review process. Every experimental or investigational appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Medicare (Original + Advantage) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Start your Medicare (Original + Advantage) experimental or investigational appeal

Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.

Start free appeal review →

Medicare (Original + Advantage) denied your experimental or investigational? Here is what to do next